A first-in-human trial of a novel designer natriuretic peptide ZD100 in human hypertension
10.1016/j.jash.2016.03.051 · doi-reference
Aldosterone levels, atrial natriuretic peptide and resistant hypertension in the general community
10.1016/j.jash.2016.03.095 · doi-reference
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics
10.1161/jaha.113.000206 · doi-reference
A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
10.1161/hypertensionaha.110.159210 · doi-reference
Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation
10.1016/j.yjmcc.2011.03.013 · doi-reference
Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease
10.1161/hypertensionaha.114.03936 · doi-reference
A randomized trial of intensive versus standard blood-pressure control
10.1056/nejmoa1511939 · doi-reference
Alternative splicing as a biomarker and potential target for drug discovery
10.1038/aps.2015.43 · doi-reference
Cenderitide-eluting film for potential cardiac patch applications
10.1371/journal.pone.0068346 · doi-reference
Delivery of short interfering ribonucleic acid-complexed magnetic nanoparticles in an oscillating field occurs via caveolae-mediated endocytosis
10.1371/journal.pone.0051350 · doi-reference
Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects
10.1177/0091270009336233 · doi-reference
Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications
10.1016/j.yjmcc.2014.08.001 · doi-reference
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
10.1371/journal.pone.0052422 · doi-reference
Novel bifunctional natriuretic peptides as potential therapeutics
10.1074/jbc.m804538200 · doi-reference
Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide
10.1172/jci116800 · doi-reference
Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide
10.1073/pnas.0811851106 · doi-reference
A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions
10.1016/j.jacc.2009.04.080 · doi-reference
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP
10.1016/j.jacc.2008.02.077 · doi-reference
A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation
10.1074/jbc.m109.010777 · doi-reference
Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions
10.1093/ehjcvp/pvv040 · doi-reference
Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload
10.1152/ajpheart.00117.2005 · doi-reference
Renal effects of ularitide in patients with decompensated heart failure
10.1016/j.ahj.2008.02.011 · doi-reference
Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial
10.1016/j.ahj.2005.01.022 · doi-reference
Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure
10.1111/j.1365-2362.1992.tb01427.x · doi-reference
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
10.1152/ajpregu.00682.2004 · doi-reference
Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies
10.1093/eurheartj/ehu484 · doi-reference
Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study
10.1253/circj.cj-08-0130 · doi-reference
10.1253/circj.cj-07-0760
10.1253/circj.cj-07-0760 · doi-reference
Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy
10.1253/circj.69.283 · doi-reference
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
10.1016/j.jacc.2012.07.056 · doi-reference
Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure
10.1002/ejhf.468 · doi-reference
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats
10.1161/circulationaha.110.981720 · doi-reference
Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial
10.1001/jama.2013.282190 · doi-reference
Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF)
10.1161/circulationaha.113.003046 · doi-reference
Effect of nesiritide in patients with acute decompensated heart failure
10.1056/nejmoa1100171 · doi-reference
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure
10.1161/01.cir.0000159340.93220.e4 · doi-reference
Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
10.1001/jama.293.15.1900 · doi-reference
